Optimal Frailty Dimensions for Assessing Frailty and Predicting Chemotherapy Adverse Events in Older Taiwanese Cancer Patients

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Jul 1

PMID 35774998

Authors

Ya-Wen Ho

Shih-Ying Chen

Yu-Shin Hung

Shinn-Yn Lin

Wen-Chi Chou

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the effects of different frailty dimensions on frailty prevalence in older Taiwanese cancer patients receiving chemotherapy, and to analyze the dimensions that should be included in frailty assessment for effectively predicting serious adverse events, unexpected hospitalizations, and emergency department visits.

Materials And Methods: This study prospectively enrolled 234 cancer patients with solid cancer or lymphoma and aged 65 years or older who later received chemotherapy at a medical center in Taiwan from September 2016 to November 2018. First, all patients were subjected to a frailty assessment on eight frailty dimensions within 1 week before their first chemotherapy treatment. The effects of different dimensions on frailty were analyzed using a Poisson regression model. Second, after sequentially excluding one, two, and three dimensions with the lowest effects, frailty was sequentially assessed in the remaining seven, six, and five dimensions for comparison of chemotherapy-related adverse events.

Results: Nutritional status, comorbidity, history of falls, cognitive status, and polypharmacy were the top five important dimensions of frailty in older Taiwanese cancer patients. Regardless of the number (five to eight) of dimensions used for frailty assessment, frail patients had higher rates of serious adverse events, unexpected hospitalizations, and emergency room visits than non-frail patients during chemotherapy.

Conclusions: Frailty assessment in older Taiwanese cancer patients should be based on at least five dimensions to accurately identify those at high risk of serious adverse events during chemotherapy. It is expected that the present findings may be used to design a frailty scale for older Taiwanese in the future.

Citing Articles

Symptoms and experiences of frailty in lung cancer patients with chemotherapy: A mixed-method approach.

Duan L, Cui H, Zhang W, Wu S Front Oncol. 2022; 12:1019006.

PMID: 36276107 PMC: 9582838. DOI: 10.3389/fonc.2022.1019006.

References

Huang Y, Hung Y, Lai C, Ho M, Yeh K, Yang C . Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy. Anticancer Res. 2021; 41(10):5213-5222. DOI: 10.21873/anticanres.15340. View

Ho Y, Yeh K, Hsueh S, Hung C, Lu C, Tsang N . Impact of early nutrition counseling in head and neck cancer patients with normal nutritional status. Support Care Cancer. 2020; 29(5):2777-2785. DOI: 10.1007/s00520-020-05804-3. View

Ho Y, Tang W, Chen S, Lee S, Chen J, Hung Y . Association of frailty and chemotherapy-related adverse outcomes in geriatric patients with cancer: a pilot observational study in Taiwan. Aging (Albany NY). 2021; 13(21):24192-24204. PMC: 8610137. DOI: 10.18632/aging.203673. View

Handforth C, Clegg A, Young C, Simpkins S, Seymour M, Selby P . The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2014; 26(6):1091-1101. DOI: 10.1093/annonc/mdu540. View

Ng T, Feng L, Nyunt M, Larbi A, Yap K . Frailty in older persons: multisystem risk factors and the Frailty Risk Index (FRI). J Am Med Dir Assoc. 2014; 15(9):635-42. DOI: 10.1016/j.jamda.2014.03.008. View

Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G . Association between cachexia, chemotherapy and outcomes in older cancer patients: A systematic review. Clin Nutr. 2016; 36(6):1473-1482. DOI: 10.1016/j.clnu.2016.12.003. View

Aparicio T, Jouve J, Teillet L, Gargot D, Subtil F, Le Brun-Ly V . Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013; 31(11):1464-70. DOI: 10.1200/JCO.2012.42.9894. View

Junius-Walker U, Onder G, Soleymani D, Wiese B, Albaina O, Bernabei R . The essence of frailty: A systematic review and qualitative synthesis on frailty concepts and definitions. Eur J Intern Med. 2018; 56:3-10. DOI: 10.1016/j.ejim.2018.04.023. View

Cohen H, Smith D, Sun C, Tew W, Mohile S, Owusu C . Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016; 122(24):3865-3872. PMC: 5138076. DOI: 10.1002/cncr.30269. View

10.

Mohile S, Dale W, Somerfield M, Schonberg M, Boyd C, Burhenn P . Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326-2347. PMC: 6063790. DOI: 10.1200/JCO.2018.78.8687. View

11.

Bossi P, Delrio P, Mascheroni A, Zanetti M . The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021; 13(6). PMC: 8226689. DOI: 10.3390/nu13061980. View

12.

Hamaker M, Jonker J, de Rooij S, Vos A, Smorenburg C, van Munster B . Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. 2012; 13(10):e437-44. DOI: 10.1016/S1470-2045(12)70259-0. View

13.

Ethun C, Bilen M, Jani A, Maithel S, Ogan K, Master V . Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin. 2017; 67(5):362-377. DOI: 10.3322/caac.21406. View

14.

Chou W, Chang P, Chen P, Wang H, Yeh K, Lu C . Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2020; 108(3):602-611. DOI: 10.1016/j.ijrobp.2020.01.004. View

15.

van der Vlies E, Kurk S, Roodhart J, Gerritse F, Pelgrim T, Vos J . The relevance of geriatric assessment for older patients receiving palliative chemotherapy. J Geriatr Oncol. 2019; 11(3):482-487. DOI: 10.1016/j.jgo.2019.05.016. View

16.

Chou W, Chang H, Wang P, Kuo M, Wu J, Lin T . Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy. Eur J Haematol. 2020; 105(4):399-407. DOI: 10.1111/ejh.13457. View

17.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

18.

Retornaz F, Guillem O, Rousseau F, Morvan F, Rinaldi Y, Nahon S . Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study. Oncologist. 2019; 25(1):e85-e93. PMC: 6964155. DOI: 10.1634/theoncologist.2019-0241. View

19.

Mohile S, Velarde C, Hurria A, Magnuson A, Lowenstein L, Pandya C . Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts. J Natl Compr Canc Netw. 2015; 13(9):1120-30. PMC: 4630807. DOI: 10.6004/jnccn.2015.0137. View

20.

Puts M, Monette J, Girre V, Wolfson C, Monette M, Batist G . Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot study. Crit Rev Oncol Hematol. 2009; 76(2):142-51. DOI: 10.1016/j.critrevonc.2009.10.006. View